Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY23 results · Jul–Sep 2022
Bliss GVS Pharma reported revenue from operations of ₹172.43 crore (down 12.0% from Q2 FY22) and net profit of ₹16.00 crore (down 27.5% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 172.43 | 195.99 | −12.0% | 188.66 | −8.6% |
| Other income | 2.15 | 5.45 | −60.5% | 7.01 | −69.3% |
| Total income | 174.58 | 201.44 | −13.3% | 195.67 | −10.8% |
| Profit before tax | 20.19 | 29.89 | −32.4% | 39.20 | −48.5% |
| Net profit for the period | 16.00 | 22.06 | −27.5% | 27.48 | −41.8% |
| Attributable to shareholders of the company | 13.85 | 21.27 | −34.9% | 25.72 | −46.1% |
| EPS, basic (₹) | 1.33 | 2.05 | −35.1% | 2.48 | −46.4% |
| Net margin (%) | 9.3 | 11.3 | 14.6 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 138.85 | 174.43 | −20.4% | 147.28 | −5.7% |
| Other income | 14.23 | 5.99 | +137.7% | 18.63 | −23.6% |
| Total income | 153.08 | 180.41 | −15.2% | 165.91 | −7.7% |
| Profit before tax | 35.29 | 34.77 | +1.5% | 32.07 | +10.1% |
| Net profit for the period | 25.45 | 24.73 | +2.9% | 24.65 | +3.3% |
| EPS, basic (₹) | 2.45 | 2.39 | +2.5% | 2.38 | +3.1% |
| Net margin (%) | 18.3 | 14.2 | 16.7 |
Consolidated
- Filed with BSE
- 21 Nov 2022, 17:22 IST
- Board meeting
- 07 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Nov 2022, 17:22 IST
- Board meeting
- 07 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE